United StatesA study conducted at Northwestern University found that patients taking the oral GLP-1 drug aleniglipron experienced up to a 12.1 percent reduction in body weight after 36 weeks. The drug, which is a small molecule, works by stimulating insulin secretion, suppressing appetite, and increasing satiety. Researchers analyzed 230 adults with overweight or obesity across 38 U.S. medical centers, who received either once-daily oral doses of aleniglipron or a placebo. Weight loss varied depending on dosage, with the highest loss observed in the 120-milligram group. Gastrointestinal side effects were reported but were mild to moderate and decreased over time. Aleniglipron is currently under development and has not been approved by the FDA.
Bias read (Center): The article presents findings from a scientific study on a new drug for weight loss. There is no indication of political bias, as the focus is on health research and does not involve political figures, policies, or contentious issues.
